Dr. Pamela M. Klein is Founder and Principal of PMK BioResearch, offering advisory and strategic consulting for biotechnology industry. She is a member of the Board of Directors of Argenx, Patrys, F-Star Therapeutics, I-Mab Biopharma and Jiya Acquisition Corporation, as well as a member of several Scientific Advisory Boards. Dr. Klein is Chief Medical Officer (consulting) of Olema Oncology and has served as Chief Medical Officer for multiple successful biotech companies including Intellikine which was acquired by Takeda. From 2001–2008, Dr. Klein held increasing positions of responsibility at Genentech, lastly as Vice President, Development, where she led the development for a portfolio of drugs including trastuzumab, rituximab, pertuzumab and erlotinib.
Prior to this, Dr. Klein was the co-founder and Research Director for the National Cancer Institute-Navy Breast Care Center.
Dr. Klein received her Bachelor’s degree in biology from California State University at Northridge and her Medical Degree from Stritch School of Medicine, Loyola University Chicago. She trained in internal medicine at Cedars-Sinai Medical Center in Los Angeles and medical oncology at the National Cancer Institute in Bethesda, Maryland where she served as Chief Fellow.